April 3, 2025 /PRNewswire/ -- Amgen announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4 ...

Uplizna is currently approved in the United States for treating adults with a rare autoimmune disease called neuromyelitis optica spectrum disorder. Following the nod, Uplizna became the first and ...

Inebilizumab was especially effective for patients with pancreatic and biliary immunoglobulin G4-related disease, with ...

Among the AChR+ patients in the Uplizna group, 69.2% improved by ≥3 points in the QMG score, compared to 41.8% in the placebo group.1 No new safety signals were identified. The overall TEAE ...

Amgen has bagged a second indication for its B cell-depleting therapy Uplizna after the FDA cleared it for rare inflammatory disease IgG4-related disease (IgG4-RD). Acquired as part of its $27.8 ...

With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth out of another drug from its $27.8 billion Horizon Therapeutics buy.

April 3 (Reuters) - The U.S. Food and Drug Administration has approved expanded use of Amgen's (AMGN.O), opens new tab drug, Uplizna, to help reduce the risk of flares in patients with a rare ...

Breakthrough CD19+ B-Cell Targeted Therapy Delivered an 87% Reduction in the Risk of Flares Versus Placebo UPLIZNA Shown to Deliver Corticosteroid-Free, Flare-Free, Complete Remission for Patients ...

UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE PR Newswire THOUSAND OAKS, Calif., April 3, 2025 Breakthrough ...